FP 004

Drug Profile

FP 004

Alternative Names: FP004

Latest Information Update: 08 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Foresee Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Opioid abuse; Pain

Most Recent Events

  • 08 Jan 2016 Early research in Opioid abuse in USA (SC) prior to January 2016 (Foresee Pharmaceuticals pipeline, January 2016)
  • 08 Jan 2016 Early research in Pain in USA (SC) prior to January 2016 (Foresee Pharmaceuticals pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top